Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects
Executive Summary
The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.